Chugai Pharmaceutical (OTCMKTS:CHGCY) Upgraded by Nomura to “Hold” Rating

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by stock analysts at Nomura to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other equities analysts also recently issued reports on the stock. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Finally, The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS:CHGCY opened at $21.57 on Tuesday. The stock’s 50-day simple moving average is $22.16 and its two-hundred day simple moving average is $25.24. The stock has a market capitalization of $71.00 billion, a price-to-earnings ratio of 23.45 and a beta of 0.59. Chugai Pharmaceutical has a 52-week low of $20.43 and a 52-week high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. As a group, equities analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.